were investigated also in the STAR*D sample. The associations between ZNF804A rs7603001 and response, CREB1 rs2254137 and remission were replicated, as well as CHL1 rs2133402 and lower risk of TRD. Other CHL1 SNPs were potential predictors of TRD (rs1516340, rs2272522, rs1516338, rs2133402). The MAPK1 rs6928 SNP was consistently associated with all the phenotypes. The protein processing in endoplasmic reticulum pathway (hsa04141) was the best pathway that may explain the mechanisms of MAPK1 involvement in antidepressant response. Signals in genes previously associated with antidepressant efficacy were confirmed for CREB1, ZNF804A and CHL1. These genes play pivotal roles in synaptic plasticity, neural activity and connectivity.
Introduction
Despite the available effective pharmacological strategies to treat patients affected by major depressive disorder (MDD), consistent unmet needs remain given the overall unsatisfactory remission rates (around 30% of subjects [1] ) and the high percent of treatment-resistance (TRD). Several definitions of TRD were formulated, but the most widely used definition is failure of consecutive treatment with two antidepressants of different classes, used for a sufficient length of time at an adequate dose [2] . This definition has been recently revised due to the increasing number of reports showing no advantage in favor of switching to a different antidepressant class [3] [4] [5] . It has been estimated that 30-40% of MDD episodes treated for an adequate duration with a recommended dose of an antidepressant exhibit treatment resistance [6] .
Genetic markers of antidepressant response and TRD have been suggested as relevant biomarkers that may provide tailored treatment options [7] . 14 genes involved in monoamine, neuroplasticity, circadian rhythm, second messenger cascade and transcription factor pathways were previously investigated in two independent samples of MDD patients [8] [9] [10] and the present study was aimed to replicate those findings in a third independent newly recruited prospective sample.
The investigated monoaminergic genes were HTR2A (serotonin (5-HT) 2A receptor) and COMT (catechol-O-methyl transferase). Regarding the former, a multi-locus model involving SNPs in the downstream-first intron region of the gene was suggested to affect antidepressant efficacy [11, 12] , while studies focused on the latter mainly investigated the rs4680 (Val108/158Met) SNP and they reported mixed findings [13] .
Among neurotrophic factors, brain derived neurotrophic factor (BDNF) is without doubt the most investigated gene and previous studies have been mainly focused on rs6265 (196G/A or Val66Met). The most recent meta-analysis suggested that the rs6265 heterozygous genotype is associated with better SSRIs response [14] . Other genes implicated in neuroplasticity are cell adhesion molecule with homology to L1CAM (CHL1), protein phosphatase 3, catalytic subunit, gamma isozyme (PPP3CC) and sialyltransferase 8B (ST8SIA2). CHL1 is a cell adhesion protein that plays a role in nervous system development and in synaptic plasticity [15] . In animal models CHL1 was associated with depressive like-behaviours [16, 17] and in lymphoblastoid cell lines (LCLs) exposed to paroxetine CHL1 was identified as the most notable genome-wide transcriptome difference between cells displaying high vs. low paroxetine sensitivity [18] . PPP3CC is a calciumdependent, calmodulin-stimulated protein phosphatase. PPP3CC may have a role in the calmodulin activation of calcineurin, a neuron-enriched phosphatase that regulates synaptic plasticity, and antagonizes the effects of the cyclic AMP activated protein/kinase A. The kinase/phosphatase dynamic balance seems to be critical for transition to longterm cellular responses in neurons [19] . ST8SIA2 may be involved in the production of polysialic acid, a modulator of the adhesive properties of neural cell adhesion molecule (NCAM1) that is involved in neuronal plasticity. The gene has previously shown association with bipolar spectrum disorder [20] . CHL1, PPP3CC and ST8SIA2 genes have not been previously investigated as predictor of antidepressant efficacy, our previous studies apart [8, 9] .
Molecules involved in second messenger cascades have been also suggested to mediate the effects of antidepressants, among them the glycogen synthase kinase 3 B (GSK3B), the phospholipase A2 group IVA (PLA2G4A) and the mitogen-activated protein kinase 1 (MAPK1). The inhibitory phosphorilation of GSK3B occurs in the context of the signaling cascades in response to 5-HT, 5-HT1 receptor agonists, dopamine, lithium, and antidepressants [21] . It plays a major role in neurodevelopment, regulation of neuroplasticity [22] and GSK-3 inhibitors have antidepressant effects in animal models [23] . The gene has been poorly studied in the field and preliminary findings pertain the promoter SNP rs334558 (−50 T/C) [24] . PLA2G4A is a calciumdependent arachidonic acid-selective cytosolic phospholipase that is found in post-synaptic sites in the brain [25] . The released arachidonic acid and its metabolites can modulate signal transduction, transcriptional regulation, neuronal activity, apoptosis and a number of other neuronal processes [26] . Further, PLA2G4A can be linked to various G-protein-coupled receptors including HTR2A [27] and ionotropic N-methyl-d-aspartate (NMDA) receptor [28] . Animal studies suggested that the gene is involved in antidepressant mechanisms of action [29] , and it has been hypothesized a risk factor for MDD [30] , but no pharmacogenetic study has been conducted, our previous study apart [8] . MAPK1 pathways represent a major convergence point in processes regulating cellular growth and differentiation, neuronal plasticity [31] [32] [33] , inflammation [34] , and stress response [35, 36] . A number of studies supported the involvement of MAPK1 in antidepressant mechanisms of action [37] [38] [39] [40] and antidepressant-induced hippocampal neurogenesis in an animal model of depression [41] . We reported previous pharmacogenetic evidence suggesting the contribution of MAPK1 to antidepressant response [10] . Cyclic AMP-responsive-element-binding protein 1 (CREB1) codes for a transcription factor that is a downstream target of MAPK pathway and its interaction with MAPK1 is of particular interest in this context. Indeed, MAPK deactivation disrupts the CREB-dependent plasticity [42] [43] [44] , as well as CREB1 phosphorylation is essential for the induction of the MAPK-dependent plasticity [43, 44] , thus MAPK1 and CREB1 have emerged as critical points of convergence in signaling pathways regulating neuronal plasticity. Some previous pharmacogenetic studies reported that CREB1 polymorphisms may modulate antidepressant response [10, 45] and TRD [46] . Other transcription factors that are hypothesized to be involved in antidepressant action are the zinc finger protein 804A (ZNF804A) and Sp4 transcription factor (SP4). ZNF804A alleles are linked to changes in neural activity and connectivity in healthy subjects [47] , as well as neuroanatomical changes in both white and grey matter in several brain regions [48] . The gene has been associated with the risk of bipolar disorder and especially psychosis [49, 50] and it is considered a crossdiagnostic candidate. SP4 is a zinc-finger brain-specific transcription factor that has been associated with MDD in two GWAS meta-analyses [51, 52] . SP4 mutant mice showed decreased granule cell density in the hippocampal dentate gyrus [53] and the gene may play a role in glutamate-induced neurotoxicity [54] .
Another group of genes that was investigated by the present study is represented by regulators of the circadian rhythm. The RAR-related orphan receptor A (RORA) gene is a member of the nuclear hormone-receptor superfamily and it has emerged as an important component of mammalian circadian rhythms [55] . A large GWAS suggested the gene as a predictor of trait depression [56] and a suggestive genome-wide association with citalopram response has been reported [57] . The vasoactive intestinal peptide receptor 2 (VIPR2) gene contribute to circadian rhythms regulation, since KO mice express disrupted behavioral and metabolic rhythms and show altered suprachiasmatic nuclei neuronal activity and clock gene expression [58] . The gene has been associated with the risk of bipolar disorder and MDD [59] , but no data exist about its possible involvement in antidepressant effect, our previous study apart [8] .
Given the existing evidence regarding the genes of interest, the present study aimed to replicate the previous pharmacogenetic findings in a prospective multi-phase trial including MDD patients that were highly characterized for treatment-resistance degree. It should be noted that this sample is completely independent from the ones investigated in previous studies and it shows different clinical characteristics compared to them [8] [9] [10] . Independent replication has always been a relevant issue in antidepressant pharmacogenetics in order to support the applicability of findings across different clinical samples. Secondly, the present study aimed to investigate the biological pathways that possibly mediate the involvement of these genes in antidepressant action.
Materials and methods

Samples
European sample 417 patients with a diagnosis of MDD who failed to respond to a previous retrospectively assessed antidepressant were entered into an open multicenter multinational two-phase naturalistic trial: in the first phase patients received a 6-week venlafaxine treatment; in the second phase those who failed to respond to venlafaxine were treated for a further 6-week period with escitalopram. The inclusion criteria were: (1) be able to read and understand the patient information sheet; (2) have signed the informed consent form; (3) be at least 18 years of age; (4) have a current major depressive episode, assessed with the Mini International Neuropsychiatric Interview (MINI), moderate or severe, according to DSM-IV-TR criteria; (5) have been treated for the current episode with any antidepressant (other than escitalopram or venlafaxine) prescribed continuously at its optimal dose for at least 4 weeks; (6) be a nonresponder to this previous treatment (Montgomery-Asberg Depression Rating Scale (MADRS) improvement <50%); and (7) have a MADRS total score ≥22. The main exclusion criteria were: (1) be a non-responder to a combination of two antidepressants and/or to an augmentation treatment at the time of screening; (2) have a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram or venlafaxine; (3) have one or more of the following conditions: (a) any current psychiatric disorder established as the principal diagnosis other than MDD as defined in the DSM-IV-TR (assessed with the MINI); (b) any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR; (c) any severe personality disorder according to investigator clinical judgment that might compromise the study; (4) have received psychotropic drugs other than antidepressants or ECT in the last period (see [2] for further details); (5) have a serious medical disease or any disorder that may represent a contraindication to the treatment with venlafaxine or escitalopram; and (6) in female patients, be pregnant or breastfeed at inclusion as well as during the study.
Initial venlafaxine daily dose was 75 mg; the daily dose could be further increased to 150 mg after 1 week, on the basis of an unsatisfactory response as judged by the investigator. If necessary, the dose could be increased up to a maximum of 225 mg, since in many countries this dose is the highest allowed and there is no specific evidence that doses higher than 225 mg are more effective. Patients who met one of the following criteria were eligible for inclusion in the escitalopram treatment phase: (1) at day 28 the patient has a MADRS total score ≥20 and a decrease in MADRS total score <25% compared to baseline; (2) at day 42 the patient has a MADRS total score ≥20 or a decrease in MADRS total score <50% compared to baseline. Initial escitalopram daily dose was 10 mg; the daily dose could be increased to 20 mg after 1 week; after 2 weeks, the daily dose could be further increased to 30 mg on the basis of an unsatisfactory response as judged by the investigator.
The severity of symptoms was assessed at baseline with the MADRS, the Hamilton Rating Scale for Depression (HRSD) 17-item version and the Clinical Global Impression Severity (CGI-S); then, symptoms were assessed every 2 weeks with the MADRS, the CGI-S and Clinical Global Impression Improvement (CGI-I).
Patients were recruited from January 2005 to December 2011 in the context of the European multicenter project, clinical results have been previously reported [2] . The study protocol was approved by the ethical committees of all participating centers and it was written in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Further details about the study protocol and outcomes are provided in a previous paper [2] . 220 patients accepted to undergo blood sample drawing for genetic analysis and they were included in the present study (see Table 1 for patients' clinical and demographic characteristics). 190 patients completed the venlafaxine treatment (86.36% of the sample), 83 patients entered into the escitalopram treatment according to the criteria reported above; 79 patients (95.18%) completed escitalopram treatment. Patients included in the pharmacogenetic study did not differ from the rest of the sample in terms of age (t = 1.27, p = 0.21) or gender (χ 2 = 0.07; p = 0.80).
Sequenced treatment alternatives to relieve depression (STAR*D)
Detailed descriptions of the study design and study population are detailed elsewhere [60] . In brief, non psychotic MDD (DSM-IV criteria) patients were enrolled from primary care or psychiatric outpatient clinics and a current 17-item Hamilton Depression Rating score of ≥14 by independent raters was obtained. Severity of depression was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C) [61] at baseline, weeks 2, 4, 6, 9, and 12. All patients received citalopram in level 1.
Phenotypes under investigation
In the European sample response and remission to venlafaxine were investigated, as well as non-response (TRDA) and non-remission (TRDB) to escitalopram (i.e. patients who responded/remitted to venlafaxine or escitalopram were compared to non-responders/non-remitters to the first and second antidepressant trials). The rationale for investigating TRDA and TRDB was based on the hypothesis that TRD may have a distinct genetic background. Nonresponse and non-remission to venlafaxine nor to escitalopram were referred as TRDA and TRDB, respectively, throughout the paper to distinguish them from response/ remission to venlafaxine. Response and remission were defined according to the MADRS (decrease of at least 50% and score of ≤10, respectively).
In the STAR*D response and remission at level 1 exit were established according to the QIDS-C (decrease of at least 50% and score of ≤5, respectively).
We did not investigate symptom improvement because: (1) remission was demonstrated to be the most clinically significant phenotype of antidepressant efficacy [62, 63] ; (2) it was not investigated by the previous studies [8] [9] [10] on the same polymorphisms; (3) it may lead more easily to spurious associations in relative small samples.
In both databases the last observation carried forward (LOCF) method was applied to manage missing data, as previously reported in papers analyzing the STAR*D [1] , when baseline and at least one post-baseline observation were available.
Aims of the study
The primary aim of the present study was to replicate the pharmacogenetic findings previously reported [8] [9] [10] in an independent prospective sample. The secondary aims were: (1) to test if other genetic polymorphisms may affect antidepressant response and TRD; (2) to improve the knowledge about the biological mechanisms that are responsible for the involvement of these genes in antidepressant efficacy by performing a pathway analysis in the STAR*D sample as described in paragraph 2.5.
SNP selection and genotyping
Genetic SNPs were chosen according to the following criteria: (1) a reported prevalence of at least 5% for the variant allele among Caucasians (MAF = 0.05 according to http:// hapmap.ncbi.nlm.nih.gov/ CEU population); (2) tagging approach [complete linkage disequilibrium (R 2 ≥ 0.08) with one or more neighbor SNPs]; (3) position within the candidate gene boundaries; and (4) availability of a validated assay in our laboratory. We also considered variants not investigated before. The list of genotyped SNPs with the corresponding Hardy-Weinberg equilibrium p values is shown in Supplementary Table 1 .
Genotypes were determined according to the previously reported methods [8] [9] [10] .
Statistical analysis
The effect of individual SNPs on phenotypes was tested through logistic regression models in the European sample. Covariates were selected according to their impact on the investigated phenotypes. A sensitivity analysis was performed excluding non-Caucasian subjects. Given that the present one is a replication study, a two-tailed alpha value of 0.05 was assumed. As additional information, we reported which associations would survive after Bonferroni correction among primary outcomes (p threshold = 0.0025) and secondary outcomes (p threshold = 0.0017). The effect of SNPs showing p < 0.05 for any of the investigated phenotypes were further analyzed through a repeated-measures mixed-effect linear regression model. In detail, the time × SNP interaction and baseline severity score were used as fixed effects and the random effect of the subject was included. Baseline severity was included in the model because it significantly affected the AIC and BIC parameters. The significance of each model was evaluated through its comparison to a null model (not including the SNP × time interaction term) using ANOVA. The R Cran lme4 package (https://cran.r-project.org/package=lme4) was used.
Given the relevance of identifying the molecular mechanisms that mediate the contribution of a gene to antidepressant action, pathways harboring one or more of the significant genes found by the analysis in the European sample were analyzed in the STAR*D. STAR*D genome-wide data were available thanks to NIMH repositories. Quality control on genome-wide data was performed according to the following criteria: (1) exclusion of subjects with more 3% missing genotypes; (2) exclusion of SNPs with >5% missing rate; (3) Hardy-Weinberg equilibrium p < 10e−05; (4) MAF < 0.01. SNPs in complete linkage disequilibrium (R 2 ≥ 0.8) were also excluded to avoid result overfitting. The KEGG database was searched to identify the pathways of interest; pathways specifically involved in processes related to cancer development/metabolism were not included. Genes belonging to each pathway under analysis were imputed using IMPUTE2 (http://mathgen.stats. ox.ac.uk/impute/impute_v2.html) and 1000 Genomes data [NCBI Build 36 (dbSNP b126)] as reference panel. An info value threshold ≥0.8 was applied in order to prune poorly imputed SNPs. Variations showing p < 0.05 and p < 0.01 in each pathway under analysis were tested for a significant different distribution (Fisher exact test) compared to a random pathway. Covariates were selected according to previous studies [8, 9] . Each random pathway was matched with the index pathway in terms of number of SNPs within it and intragenic position of the SNPs but with random distribution within the genome. 10e04 permutations were run for pathways showing nominal association with phenotypes.
Power analysis
A sample size of 220 provides 0.80 power to detect a polymorphism with OR = 2.3 and MAF = 0.30 (that is in line with the MAF of the most part of the investigated polymorphisms) setting alpha value to 0.05 two-tailed. G*Power 3.1 was used for power estimation [64] . Alpha value was set to 0.05 since the replication aim of the study.
Results
The clinical-demographic characteristics of patients and the comparison between the venlafaxine and escitalopram groups are reported in Table 1 . The chances of response and remission drastically dropped when patients entered into the escitalopram phase (from 77.5 to 49.4% and from 43.4 to 22.9%, respectively). 30 patients did not complete venlafaxine treatment but they did not differ compared to completers in terms of mean age (t = −0.69, df = 200.81, p = 0.49), baseline severity (t = −1.01, df = 39.04, p = 0.32), anxious (X-squared = 1.00, df = 1, p = 0.32) or melancholic features (X-squared = 0.04, df = 1, p = 0.85), suicidal ideation severity (X-squared = 2.06, df = 2, p = 0.36), and venlafaxine mean dose at week 2 (t = −1.58, df = 24.74, p = 0.13). Anyway, there was a slight prevalence of females among drop-out patients (X-squared = 5.03, df = 1, p = 0.02). Eight patients were excluded from the analysis because they did not have any post-baseline evaluation.
Baseline MADRS score affected response (p = 0.001) and remission (p = 5.24e−05) to venlafaxine, as well as TRDB (p = 5.74e−06); suicidal risk affected the risk of TRDB (p = 0.0029). Thus, these variables were included as covariates in the corresponding analysis. Response and remission to venlafaxine were associated with venlafaxine dose, but we suggest this was due the prescription of higher doses to patients who showed lower symptom improvement, thus dose was not included among covariates.
European sample
Primary outcomes
The association of ZNF804A rs7603001 G allele with response and CREB1 rs2254137 AA with remission were successfully replicated (Table 2) . Further, we found a trend showing lower TRDA risk in CHL1 rs2133402 GG carries ( Table 3 ). The PLA2G4A rs10489407 and BDNF rs11030104 showed evidence of association with remission (Table 2 ) but in the opposite direction compared to what expected [8] . Results were similar when restricting the analysis to Caucasian subjects (Supplementary Table 2 ). ZNF804A rs7603001 was also associated with symptom improvement over time (Table 4) . None of these associations would survive after Bonferroni correction. Other associations previously reported [8] [9] [10] were not replicated.
Secondary outcomes
Findings with p < 0.05 are shown in Table 2 for venlafaxine response and remission. Better response to venlafaxine was associated with SNPs in the PLA2G4A gene (rs6695515 GT, rs6695515 T allele and rs10737276 GC genotype), ZNF804A gene (rs7603001 GG genotype and G allele) and CHL1 gene (rs1516340 CT genotype). MAPK1 SNPs were associated with both venlafaxine response and remission (rs6928 GG genotype and G allele predicted better response and remission), as well as HTR2A rs17288723 T allele carriers showed both worse response and remission. Remission to venlafaxine was associated with rs6265 G (or Val) allele in the BDNF gene. Results were similar when restricting the analysis to Caucasian subjects (Supplementary Table 2 ).
Findings with p < 0.05 are shown in Table 3 for TRDA and TRDB. Several CHL1 SNPs were associated with the risk of TRDA: rs1516340 CT genotype showed lower risk of TRDA, as well as rs2272522 CT genotype and rs1516338 C allele carriers. Some variants that were also associated with venlafaxine response and remission predicted both the risk of lower TRDA and/or TRDB: PLA2G4A rs6695515 GT genotype and T allele, MAPK1 rs6928 G allele, and rs6928 GG genotype.
Mixed-effects linear regression models supported the effects of HTR2A rs17288723, PLA2G4A rs6695515 and rs10737276, CHL1 rs1516340 and rs2272522 on symptom improvement during venlafaxine treatment (Supplementary Fig. 1 ), while of CHL1 rs1516340 and MAPK1 rs6265 on symptom improvement during escitalopram treatment ( Supplementary Fig. 2) . Results of mixed-effects linear regression models showing p < 0.05 are reported in Table 4 while other results are available upon request.
An overview of all findings is reported in Supplementary  Table 3 for venlafaxine response and remission and in Supplementary Table 4 for TRDA and TRDB. The only results that would survive after Bonferroni correction are MAPK1 rs6928 allelic association with remission (p = 0.0006, see Table 2 ), HTR2A rs17288723 and PLA2G4A rs10737276 association with symptom improvement during venlafaxine treatment (p = 0.00011 and p = 0.00044, respectively, see Table 4 ).
STAR*D
1846 patients were included in the analysis (Supplementary Table 5 shows sample clinical-demographic characteristics). No KEGG pathway including the genes reported in paragraph 3.1 was associated with the outcomes in the STAR*D (Supplementary Table 6 and  Supplementary Table 7 for response and remission, respectively). The protein processing in endoplasmic 
Discussion
Main findings
The present study investigated genetic predictors of antidepressant efficacy (response, remission and treatment-resistance) with the aim to replicate previous findings in genes involved in monoaminergic neurotransmission (HTR2A, COMT), neuroplasticity (BDNF, CHL1, ITGB3, GAP43, ST8SIA2, PPP3CC, PLA2G4A, GSK3B), circadian rhythm (RORA, VIPR2), and transcription factor activity (ZNF804A, SP4). Using a prospective sample sequentially treated with venlafaxine and escitalopram, we replicated the association of ZNF804A rs7603001 G allele with response [8] and CREB1 rs2254137 AA genotype with remission [10] . Further, we found a trend showing lower TRDA risk in CHL1 rs2133402 GG carries, that is in line with our previous finding of better remission in G allele carriers [9] . Interestingly, several CHL1 SNPs (rs1516340, rs2272522, rs1516338, rs2133402) were associated with treatmentresistance in this study, further suggesting the relevance of this gene. The PLA2G4A rs10489407 and BDNF rs11030104 showed evidence of association with remission but in the opposite direction compared to what previously reported [8] . In addition to rs10489407, a couple of PLA2G4A SNPs (rs6695515 and rs10737276) were associated with clinical outcomes in the present study, but negative findings were reported for these two SNPs in a previous study [8] . The result observed for the BDNF rs6265 (Val66Met) SNP did not show replication in our previous studies, but it had some support in literature. This SNP was repeatedly associated with antidepressant efficacy, as confirmed by the most recent meta-analysis [14] that reported better treatment outcome in the heterozygote genotype. In the present study the G (Val) allele was associated with better venlafaxine remission, while no effect of the heterozygote genotype compared to the homozygote genotypes was found (p = 0.11, not shown among the main results), possibly due to the low number of AA subjects (n = 6) that flattened the comparison G/A vs. GG + AA to G/A vs. GG. Anyway, in humans the A (Met) allele was associated with poorer episodic memory, abnormal hippocampal activation and metabolism [65] . In mice, the Met/Met genotype did not show any increase in hippocampus BDNF levels during fluoxetine treatment and had impaired survival of newly born cells in the dentate gyrus [66] . Thus, Val allele carriers or heterozygote subjects are possibly the groups showing better response according to the present study and literature. MAPK1 rs6928 was consistently associated with all the phenotypes investigated by the present study, but negative findings were previously reported for this SNP [10] , thus no conclusion can be traced. HTR2A rs17288723 was associated with response, but again no replication was achieved for this SNP. The heterogeneity between this sample and the previous one may be responsible for the non-replicated findings, particularly the different pharmacological treatments (the previous sample was treated in a naturalistic setting, including different antidepressants, antidepressant combinations, and augmentation treatments [10] ).
A pathway analysis was performed on the STAR*D sample to investigate the molecular mechanisms that may be responsible for the observed genetic associations. Anyway, no pathway was associated with clinical outcomes, but the protein processing in endoplasmic reticulum pathway (hsa04141) showed a nominal association with response (p = 0.017) that did not survive permutations. The top genes within this pathway were PARK2 (Parkin RBR E3 Ubiquitin Protein Ligase), DERL2 (Derlin 2), MAN1A2 (Mannosidase, Alpha, Class 1A, Member 2), TUSC3 (Tumor Suppressor Candidate 3), SIL1 (SIL1 Nucleotide Exchange Factor), SEL1L2 (Sel-1 Suppressor Of Lin-12-Like 2), MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5), and BCL2 (B-Cell CLL/Lymphoma 2). In the view of antidepressant mechanisms of action, the most interesting genes within this group are BCL2 and PARK2. The anti-apoptotic protein B-cell/lymphoma 2 inhibits most types of apoptotic and necrotic cell death, and also seems to act as a major regulator of neural plasticity and cellular resilience [67, 68] . Several antidepressants were demonstrated to increase the expression of BCL2, among which venlafaxine [69] , fluoxetine [70] , reboxetine, tranylcypromine [71] , agomelatine [72] , as well as gene expression in increased during electroconvulsive shockmediated induction of neurogenesis [73] . Drug-free MDD patients were demonstrated to have lower BCL2 mRNA levels than healthy controls and antidepressant treatment was reported to increase BCL2 mRNA levels. Further, the BCL2 rs2279115 C allele was associated with TRD and affected gene expression levels [74] . Mutations in the PARK2 gene are involved in the pathogenesis of an earlyonset form of Parkinson's disease (PD) that can show concomitant depressive and/or psychotic symptoms [75] [76] [77] . Subjects with mutations in PD genes (even not specifically in the PARK2 gene) were demonstrated to show more commonly concomitant depression compared to patients with idiopathic PD [78] .
Limitations
The limitations of this study should be considered. Firstly, the sample size of the original sample was relatively small. Anyway, subjects were prospectively treated and therefore recall bias of retrospective studies has been avoided, further, our sample size was expected to provide enough power to identify risk variants with OR = 2.3, that is in line with the OR of the findings with p < 0.05 reported by this study. We proposed that correction for multiple testing was not mandatory since the replication nature of the study, but the results that would survive after Bonferroni correction were specified in the Results section. None of associations that replicated previous findings (i.e. primary outcomes) would survive after Bonferroni correction. Among secondary outcomes, only MAPK1 rs6928 allelic association with remission, HTR2A rs17288723 and PLA2G4A rs10737276 association with symptom improvement during venlafaxine treatment would survive after multiple-testing correction. Secondly, this study primarily aimed to replicate the pharmacogenetic findings obtained in another sample [8] [9] [10] , but heterogeneity between the two samples may have confounded results. Finally, other polymorphisms (e.g. variants in the CYP2D6 and CYP2C19 genes associated with modifications in the metabolizing level) were not genotyped in this study but they may have affected the risk of nonresponse or TRD.
Conclusions
The present study replicated the association of the ZNF804A rs7603001 G allele with antidepressant response [8] and CREB1 rs2254137 AA genotype with remission [10] . Further, CHL1 rs2133402 GG and G allele carries may show lower risk of TRD and better remission in line with previous findings [9] . Other CHL1 SNPs are potential predictors of TRD (rs1516340, rs2272522, rs1516338, rs2133402) and BDNF rs6265 Val allele was associated with remission in line with previous findings in literature. The MAPK1 rs6928 SNP was consistently associated with all the investigated phenotypes including treatmentresistance, but negative findings were previously reported. The protein processing in endoplasmic reticulum pathway (hsa04141) was the best pathway that may explain the mechanisms by which MAPK1 may be involved in antidepressant response.
